ifedipine on Pregnancy Rates in ICSI cycles

Phase 3

Recruiting

Conditions: Recurrent Implantation failure in IVF.

Registration Number: IRCT20180417039338N3

Lead Sponsor: Babol University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Female

Target Recruitment: 100

Inclusion Criteria

1.Women 18-40 yr with BMI<38 undergo ICSI treatment and freeze embryo transfer candidate are participated in this study.2. Blood pressure >= 100/60, 3. FSH <14mli/IU. 4. abnormal uterus in HSG or hystroscopy. 5. who do not contraindicate the use of nifedipine, such as heart and liver 6. Patients who do not have a history of irregular heart rate or who do not use hypotention medication.

Exclusion Criteria

Patients who have been taking medication with nifedipine over a month have interfered with drugs such as benzodiazepines, flecainide, imipramine, propafenone, azole antifungals, cimetidine, cyclosporine, erythromycin, quinidine, terfenadine, warfarin and theophylline. 2.Those who have blood pressure of 60/100 (mmHg) or less before embryo transfer

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pregnancy rate( hCG>31IU/LI) 12 days following embryo transfer. Timepoint: 12 days following embryo transfer. Method of measurement: Blood test, BHCG.

Secondary Outcome Measures

Name	Time	Method
Implantation rate: Gestational sac. Timepoint: in 6 weeks after pregnancy. Method of measurement: vaginal sonography.;Clinical pregnancy, Fetal heart rate observation. Timepoint: 6-8 after pregnancy. Method of measurement: vaginal sonography.;Spontaneous abortion. Timepoint: before 20 week pregnancy. Method of measurement: vaginal sonography.;Complications of pregnancy and infant including multiple or ectopic pregnancy, spotting and vaginal bleeding. Timepoint: in 3 months pregnancy. Method of measurement: vaginal sonography.